Table 1.
Patient characteristics during the baseline period
| Characteristic baseline subgroup | Placebo (N = 476) | Reslizumab (N = 477) |
|---|---|---|
| Mean age (SD), years | 47.1 (14.3) | 46.5 (13.8) |
| Females, n (%) | 311 (65) | 286 (60) |
| Mean body mass index (SD), kg/m2 | 27.5 (5.7) | 27.4 (5.8) |
| Oral corticosteroid use, n (%) | 73 (15) | 73 (15) |
| LABA use, n (%) | 383 (80) | 397 (83) |
| High-dose ICSa use, n (%) | 208 (44) | 203 (43) |
| Mean FEV1 (SD), mL | 1965 (734) | 2008 (763) |
| EOS < 150 cells/µL | 1947 (643) | 2317 (834) |
| EOS 150 to < 400 cells/µL | 2101 (759) | 2032 (734) |
| EOS 400 to < 700 cells/µL | 1997 (795) | 2091 (785) |
| EOS ≥ 700 cells/µL | 1860 (655) | 1846 (710) |
| FEV1 reversibility < 14% | 2258 (735) | 1975 (754) |
| FEV1 reversibility 14 to < 16% | 2187 (666) | 2180 (659) |
| FEV1 reversibility 16 to 20% | 1944 (838) | 2045 (821) |
| FEV1 reversibility ≥ 20% | 1841 (678) | 1979 (763) |
| Mean FEV1 predicted (SD), % | 66.5 (19.4) | 66.9 (20.0) |
| Mean FEV1 reversibility (SD), % | 27.5 (21.1) | 27.0 (15.8) |
| Mean FVC (SD), mL | 3008 (1030) | 3070 (1010) |
| Mean blood EOS (SD), cells/µL | 655 (637) | 654 (621) |
| Mean age of asthma onset (SD), years | 27.8 (17.9) | 27.3 (18.4) |
aHigh-dose ICS use was defined as when one of the following was true at enrolment: fluticasone > 500 µg/day, mometasone > 440 µg/day, budesonide > 800 µg/day, ciclesonide > 320 µg/day, beclomethasone > 400 µg/day or triamcinolone > 2000 µg/day
EOS eosinophil, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting beta agonist, SD standard deviation